Veracyte to Release Q1 2026 Results on May 5

Webcast and conference call scheduled after market close on earnings release date.

Apr. 14, 2026 at 8:05pm

Got story updates? Submit your updates here. ›

A polished, geometric medical device or diagnostic instrument made of premium materials like stainless steel, glass, and carbon fiber, arranged elegantly on a clean, monochromatic background and dramatically lit to showcase the precision and innovation of Veracyte's cancer diagnostics technology.Veracyte's advanced cancer diagnostics technology takes center stage in this high-end studio still life, hinting at the company's commitment to precision and innovation.South San Francisco Today

Veracyte, a leading cancer diagnostics company, announced that it will release its financial results for the first quarter of 2026 after the market close on Tuesday, May 5, 2026. The company will host a conference call and webcast at 4:30 p.m. Eastern Time on the same day to discuss the financial results and provide a general business update.

Why it matters

As a prominent player in the cancer diagnostics industry, Veracyte's quarterly earnings reports provide insights into the company's performance and the broader trends in the sector. Investors and analysts will be closely watching the Q1 2026 results for signs of the company's growth, market share, and the adoption of its diagnostic tests.

The details

Veracyte will release its Q1 2026 financial results after the market close on May 5, 2026. The company will then host a conference call and webcast at 4:30 p.m. Eastern Time on the same day to discuss the results and provide a general business update. A webcast replay will be available on the company's website following the conclusion of the live broadcast.

  • Veracyte will release its Q1 2026 financial results after the market close on May 5, 2026.
  • The company will host a conference call and webcast at 4:30 p.m. Eastern Time on May 5, 2026 to discuss the results.
  • A webcast replay will be available on the company's website following the conclusion of the live broadcast.

The players

Veracyte, Inc.

A leading cancer diagnostics company that empowers clinicians with high-value insights to guide and assure patients at pivotal moments in the race to diagnose and treat cancer.

Kelly Gura

Investor relations contact for Veracyte.

Molly Cornbleet

Media contact for Veracyte.

Got photos? Submit your photos here. ›

What’s next

Investors and analysts will be closely watching Veracyte's Q1 2026 earnings report and conference call for insights into the company's performance, market trends, and future growth prospects.

The takeaway

Veracyte's upcoming Q1 2026 earnings release and conference call will provide valuable information about the company's position in the cancer diagnostics market and its ability to continue driving innovation and growth in the sector.